source
- Lilly uses indirect data to argue its oral GLP-1 pill may outperform Novo’s semaglutideEli Lilly’s weight‑loss drug Foundayo has seen a slower launch than expected, according to BMO Capital Markets, which noted the product is lagging behind competitors. To bolster its market case, L…
- AI chemistry agent gives wrong answer after handling malformed data, highlighting safety concerns in drug researchAn AI chemistry agent called ChemAgent was tasked with checking whether a molecule had a known hepatobiliary side effect. The agent supplied the molecular structure in an invalid format to a speci…